ASP2151

11/01/2017 - "In conclusion, amenamevir 400 mg appears to be effective and well tolerated for treatment of herpes zoster in immunocompetent Japanese patients."
10/01/2023 - "Real-world safety and efficacy of amenamevir in patients with herpes zoster in Japan: A postmarketing observational study (REWARD)."
01/01/2019 - "Efficacy of amenamevir for the treatment of herpes zoster in an immunocompromised patient: Report of a case."
07/01/2022 - "A 73-year-old man developed herpes zoster around the right eye, and oral amenamevir treatment was given for seven days. "
05/01/2022 - "A total of 785 herpes zoster patients treated with amenamevir were followed up for 12 months. "

04/01/2012 - "Three-day or single-day courses of ASP2151 appear to be effective and safe options for treatment of episodes of recurrent genital herpes. "
10/01/2022 - "Patient-initiated single-dose amenamevir reduced the time to all lesion healing of recurrent genital herpes versus placebo, with no safety concerns, suggesting it could be an effective treatment option for patients with recurrent genital herpes. "
01/01/2014 - "We present a first population pharmacokinetic (PPK) modeling analysis of Amenamevir for genital herpes patients. "
01/01/2014 - "Phase II randomized trial assessed the safety and efficacy of ASP2151 for episodic therapy of recurrent genital herpes was conducted. "
04/01/2012 - "This randomized trial assessed the safety and efficacy of ASP2151 for episodic therapy of recurrent genital herpes. "

06/01/2022 - "Amenamevir could thus be a treatment option for severe varicella zoster virus infections."
12/01/2018 - "Amenamevir was not affected by the host's immune status in terms of effective oral doses and was more efficacious in treating severe cutaneous infection even when treatment initiation was delayed."
03/01/2017 - "ASP2151 suppressed HSV replication more efficiently than ACV at 10 × 50% effective concentration of plaque formation (EC50), when treatments were started 0-24 h after infection. "
03/01/2013 - "Here, to determine and analyze the correlation between the pharmacodynamic (PD) and pharmacokinetic (PK) parameters of ASP2151, we examined the PD profile of ASP2151 using in vitro plaque reduction assay and a murine model of HSV-1 infection. "
08/25/2011 - "Oral ASP2151 given from the day of infection reduced peak and overall disease scores in a dose-dependent manner, resulting in complete prevention of symptoms at the dose of 30 mg/kg. The 50% effective dose (ED(50)) values for ASP2151 and VACV were 0.37 and 68 mg/kg, respectively, indicating that ASP2151 was 184-fold more potent than VACV. "

11/01/2017 - "Helicase-primase inhibitor amenamevir for herpesvirus infection: Towards practical application for treating herpes zoster."
12/01/2018 - "Antiviral efficacy of the helicase-primase inhibitor amenamevir in murine models of severe herpesvirus infection."
11/01/2018 - "Amenamevir (formerly ASP2151) is a helicase-primase inhibitor being developed for the treatment of herpesvirus infection. "

06/01/2022 - "The Efficacy of Amenamevir for the Treatment of Disseminated Herpes Zoster Complicated with Probable Varicella-zoster Pneumonia in an Immunocompromised Patient."
06/01/2022 - "This is the first report suggesting the efficacy of amenamevir in the treatment of severe herpes zoster infection with coexisting DHZ and probable varicella-zoster pneumonia. "
04/21/2021 - "[Varicella-zoster meningoencephalitis and vasculitis after treatment with amenamevir to herpes zoster in the trigeminal nerve area]."
02/20/2021 - "We discuss VZV diseases and the decrease in their incidence due to the introduction of live-attenuated vaccines to prevent varicella or HZ. We also focus on acyclovir, valacyclovir, and famciclovir (FDA approved drugs to treat VZV infections), brivudine (used in some European countries) and amenamevir (a helicase-primase inhibitor, approved in Japan) that augur the beginning of a new era of anti-VZV therapy. "